Clinical trial
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced…
NCT00004036 · The Cleveland Clinic, Other · Unknown status
Key facts
| NCT number | NCT00004036 |
|---|---|
| Title | Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer |
| Official title | Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide |
| Enrollment | 30 |
| Start date | Nov 1, 1997 |
| First posted | Sep 13, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: